4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
9.85
-0.06 (-0.61%)
Jun 1, 2026, 1:15 PM EDT - Market open
4D Molecular Therapeutics Revenue
4D Molecular Therapeutics had revenue of $3.05M in the quarter ending March 31, 2026, with 21,664.29% growth. This brings the company's revenue in the last twelve months to $88.24M, up 383,560.87% year-over-year. In the year 2025, 4D Molecular Therapeutics had annual revenue of $85.21M with 230,194.59% growth.
Revenue (ttm)
$88.24M
Revenue Growth
+383,560.87%
P/S Ratio
5.98
Revenue / Employee
$450,214
Employees
196
Market Cap
514.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 85.21M | 85.17M | 230,194.59% |
| Dec 31, 2024 | 37.00K | -20.69M | -99.82% |
| Dec 31, 2023 | 20.72M | 17.59M | 562.29% |
| Dec 31, 2022 | 3.13M | -14.91M | -82.65% |
| Dec 31, 2021 | 18.04M | 4.43M | 32.52% |
| Dec 31, 2020 | 13.61M | 6.63M | 94.85% |
| Dec 31, 2019 | 6.99M | -7.14M | -50.56% |
| Dec 31, 2018 | 14.13M | 8.34M | 144.04% |
| Dec 31, 2017 | 5.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 389.42M |
| Gyre Therapeutics | 117.05M |
| Autolus Therapeutics | 92.62M |
| Prothena Corporation | 57.94M |
| XOMA Royalty | 48.56M |
| Editas Medicine | 38.69M |
| Ovid Therapeutics | 7.12M |
FDMT News
- 5 days ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 12 days ago - 4D Molecular Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 16 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 18 days ago - 4D Molecular Therapeutics Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 24 days ago - 4D Molecular price target lowered to $33 from $38 at Goldman Sachs - TheFly
- 24 days ago - 4D Molecular files $400M mixed securities shelf - TheFly
- 24 days ago - 4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire
- 25 days ago - 4D Molecular Therapeutics Registration statement: Registration filing - Filings